# SKB264 Plus Inetetamab in HER2-Positive Metastatic Breast Cancer Patients Progressing After T-DXd Treatment

> clinical trial · VERIFIED · 2026-07-15

Status: RECRUITING · Sponsor: Fudan University · Condition: HER2-positive, Unresectable, Locally Advanced or Metastatic Breast Cancer

- Company: Fudan University
- Sector: HER2-positive, Unresectable, Locally Advanced or Metastatic Breast Cancer
- Primary source: https://clinicaltrials.gov/study/NCT07182721

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.